It joins a number of other BCMA-directed therapies for multiple myeloma, including GSK's first-to-market antibody-drug conjugate Blenrep (belantamab mafodotin), Bristol-Myers Squibb/bluebird bio's ...

Multiple myeloma (MM), which is caused by the transformation and uncontrolled proliferation of blood cells that normally produce antibodies 1, is the second most common haematological cancer ...